Levetiracetam as a treatment for tardive dyskinesia: a case report.
McGavin
Cameron L
CL
Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, PA 15213, USA. mcgavinc@msx.upmc.edu
John
Vineeth
V
Musser
William S
WS
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D002908:Chronic Disease; D003000:Clonidine / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000150:complications / Q000188:drug therapy; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D000077287:Levetiracetam; D016651:Lithium Carbonate / Q000009:adverse effects; D008875:Middle Aged; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D000927:Anticonvulsants; D000928:Antidepressive Agents; D016651:Lithium Carbonate; D000077287:Levetiracetam; D003000:Clonidine; D010889:Piracetam